{"nctId":"NCT02597478","briefTitle":"Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea","startDateStruct":{"date":"2016-01-04","type":"ACTUAL"},"conditions":["Advanced Cancers"],"count":50,"armGroups":[{"label":"Low-Dose Fentanyl Spray Group","type":"EXPERIMENTAL","interventionNames":["Drug: Fentanyl Sublingual Spray","Procedure: Shuttle Walk Test","Behavioral: Questionnaires","Behavioral: Mental Ability Tests","Behavioral: Phone Call"]},{"label":"High-Dose Fentanyl Spray Group","type":"EXPERIMENTAL","interventionNames":["Drug: Fentanyl Sublingual Spray","Procedure: Shuttle Walk Test","Behavioral: Questionnaires","Behavioral: Mental Ability Tests","Behavioral: Phone Call"]}],"interventions":[{"name":"Fentanyl Sublingual Spray","otherNames":["Fentanyl SL Spray","FSS"]},{"name":"Shuttle Walk Test","otherNames":[]},{"name":"Questionnaires","otherNames":["Surveys"]},{"name":"Mental Ability Tests","otherNames":[]},{"name":"Phone Call","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Diagnosis of cancer with evidence of active disease\n2. Breakthrough dyspnea, defined as dyspnea with an average intensity level over the past 7 days of at least 3/10 on a numeric rating scale upon significant exertion or continuous dyspnea \\</=7/10 with worsening upon significant exertion\n3. Outpatient at MD Anderson Cancer Center seen by the Supportive Care Service, Thoracic Medical Oncology, Cancer Pain Clinic, or Cardiopulmonary clinic\n4. Ambulatory and able to walk with or without walking aid\n5. On strong opioids with morphine equivalent daily dose of 80-500 mg for at least one week, with stable (i.e. +/- 30%) regular dose over the last 24 hours\n6. Karnofsky performance status \\>/=50%\n7. Age 18 or older\n8. Able to complete study assessments\n\nExclusion Criteria:\n\n1. Dyspnea at rest \\>/=7/10 at the time of enrollment\n2. Supplemental oxygen requirement \\>6 L per minute\n3. Delirium (i.e. Memorial delirium rating scale \\>13)\n4. History of unstable angina or myocardial infarction 1 month prior to study enrollment\n5. Resting heart rate \\>120 at the time of study enrollment\n6. Systolic pressure \\>180 mmHg or diastolic pressure \\>100 mmHg at the time of study enrollment\n7. History of active opioid abuse within the past 12 months\n8. History of allergy to fentanyl\n9. Severe anemia (Hb \\<7g/L) if documented in the last month and not corrected prior to study enrollment\\*\n10. Diagnosis of acute pulmonary embolism within past 2 weeks\n11. Diagnosis of pulmonary hypertension\n12. Unwilling to provide informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Modified Dyspnea Borg Scale (Dyspnea Intensity)","description":"The primary outcome was dyspnea intensity \"now\" using the modified Borg scale, which ranges from 0 (\"no shortness of breath\") to 10 (\"worst possible shortness of breath\"). We measured the change in modified dyspnea Borg scale (0-10) between the first and second shuttle walk tests. This scale has been validated in multiple studies, with a minimal clinically significant difference of 1 point.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":null},{"groupId":"OG001","value":"-0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Modified Dyspnea Borg Scale (Dyspnea Unpleasantness)","description":"The modified Borg scale (dyspnea unpleasantness), which ranges from 0 (\"no shortness of breath\") to 10 (\"worst possible shortness of breath\"). We measured the change in modified dyspnea Borg scale (0-10) between the first and second shuttle walk tests.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.8"},{"groupId":"OG001","value":"-0.6","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Walk Distance","description":"We measured the difference in walk distance (in meters) between the first and second shuttle walk tests.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.7","spread":null},{"groupId":"OG001","value":"24.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Walk Time","description":"We measured the difference in walk time (in minutes) between the first and second shuttle walk tests.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Fatigue Modified Borg Score","description":"The fatigue modified Borg scale, which ranges from 0 (\"none\") to 10 (\"worst\"). We measured the change in modified fatigue Borg scale (0-10) between the first and second shuttle walk tests.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"2.8"},{"groupId":"OG001","value":"0.2","spread":"1.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["Dizziness","Drowsiness","Itchiness"]}}}